Medley-Cipla deal talks called off over valuation issues

This is the second pharma merger and acquisition (M&A) transaction that has been called off or postponed recently due to market volatility and valuation mismatch. Hyderabad-based Aurobindo Pharma had also scrapped the demerger and sale of its injectables arm Eugia Pharma Specialities to Blackstone earlier this year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/P6XUVqb
via IFTTT